The Saudi Food and Drug Authority (SFDA) announced that its CEO participated in visits to leading medical and research institutions in the United States to explore advancements in biotechnology and advanced therapies. The initiative supports the SFDA’s efforts to strengthen regulatory capabilities, enhance oversight of innovative therapies, and align with international best practices.

Key highlights:

  • SFDA leadership engaged with leading US medical and research institutions to gain insights into advanced therapeutic technologies
  • The visit included participation in the Drug Information Association (DIA) Annual Meeting, facilitating knowledge exchange on emerging regulatory trends
  • Discussions focused on advanced therapies, including CAR-T cell therapies and gene-editing technologies
  • Visits to renowned institutions, including the Children's Hospital of Philadelphia and University of Pennsylvania research facilities, provided exposure to cutting-edge research and development
  • The delegation reviewed current clinical trial approaches, manufacturing practices, and commercialization pathways for advanced therapeutics
  • Engagements explored expanding therapeutic applications for oncology, genetic disorders, and immunological diseases
  • Regulatory oversight models and manufacturing frameworks for advanced therapy medicinal products were assessed
  • The initiative aims to enhance SFDA’s preparedness for evaluating and regulating innovative biopharmaceutical products
  • Insights gained will support the modernization and efficiency of Saudi Arabia’s regulatory framework for advanced therapies
  • The activity aligns with Saudi Vision 2030 and the National Biotechnology Strategy, supporting healthcare innovation and biotechnology sector growth
  • The visit further strengthens international collaboration and knowledge-sharing with global research and healthcare institutions

This development signals Saudi Arabia’s continued commitment to building a future-ready regulatory framework for advanced therapies and positioning the country as a regional hub for biotechnology innovation.

Consult Now

Source
https://www.sfda.gov.sa/en/news/5521958
Select Mandate HA
SFDA
Select Mandate Function
Regulatory Affairs